Global Precision Medicine Market to Approach US$ 106.1 Billion by the end of 2025

National Cancer Institute (NCI) conducts NCI-COG Pediatric MATCH trial that enrolls children and adolescents by advanced cancer therapy based on their genetic abnormality, where NCI also plans to support new immunotherapy clinical trials, antibody, testing of new combinations of the cell, small molecule, and radiation therapy studies, which include sequencing of tumor specimens. In July 2017, NCI has also launched various precision medicine trials, which include Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials (ALCHEMIST), Lung Cancer Master Protocol (Lung-MAP), Molecular Analysis for Therapy Choice (NCI-MATCH), and Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT).

This report segments the global precision medicine market on the basis of technology and application. On the basis of technology, the global precision medicine market is segmented into bioinformatics, gene sequencing, drug discovery, precision molecular diagnostics, and big data analytics. Applications of precision medicine include oncology, CNS, hematology, respiratory, and immunology, among others.

Request for a sample copy @ https://www.coherentmarketinsights.com/insight/request-sample/145

Global Precision Medicine Market Segmentation Forecast:
Global Precision Medicine Market, By Technology:
Bioinformatics,Gene Sequencing,Drug Discovery,Precision Molecular Diagnostics,Big Data Analytics
Global Precision Medicine Market, By Application:
Oncology,Breast cancers,Lung Cancer,Others,.
CNS,Hematology,Respiratory,Immunology,Others,.

Furthermore, precision medicine is proving to be effective in treating oncology-related diseases, cardiovascular diseases, psychiatric disorders, neurodegenerative diseases, arthritis, obesity, diabetes, pain, and Alzheimer’s disease. Reduced cost of treatment attracts patient toward the precision medicine, as precision medicine cuts down most of the expensive treatments, which are not required since genetic testing helps the oncologists offer precision medicine.

Get Exclusive Discount on This Report: https://www.coherentmarketinsights.com/insight/request-discount/145

Key features of the study:

This report provides an in-depth analysis of precision medicine in medical sector and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2016 – 2024), considering 2015 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, product pipeline, regional outlook, and competitive strategy adopted by the leading players

It profiles leading players in the global precision medicine market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans

Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion and marketing tactics
Some of the key players in the market are:
Novartis AG.
Intomics.
Ferrer Incode.
Nanostring Technologies, Inc.
Pfizer, Inc.
Teva Pharmaceuticals.
Merck & Co., Inc.
Qiagen N.V.
Quest Diagnostics.

Complete Report Details: https://www.coherentmarketinsights.com/market-insight/precision-medicine-market-145

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.